GF/B46/ER14 - Board Decision - Approval of the Secretariat’s Recommendation on Funding from the 2021 COVID-19 Response Mechanism

Sep 12, 2026

Upload by Đào

Board submission proposing a decision on approving Secretariat funding recommendations under the 2021 COVID-19 Response Mechanism for Multicountry ECSA-HC, up to US$1,819,230. The paper documents the Board’s context and references prior decision requirements, outlines how country awards were reviewed through internal processes and partner technical inputs, and specifies review criteria including strategic alignment, WHO guidance, program linkage, stakeholder engagement, procurement feasibility, technical soundness, budget assumptions, complementarity, fiduciary risk mitigation, and value for money. It also delegates to the Secretariat authority to redistribute funding ceilings among constituent grants.

LanguageEnglish

CategoryLetters

FormatPDF

Pages9

Reading Time3 min

AccessFree to download

Purpose of the paper

Decision

Decision point: GF/B46/EDP18

Executive Summary

Context and Input Received

Input Sought

Table 1: Secretariat’s Recommendation on Funding from C19RM

Electronic Report to the Board Secretariat’s Recommendations on Funding from the COVID-19 Response Mechanism GF/B46/ER14 Board Decision Purpose of the paper: This document proposes the following decision point: GF/B46/EDP 18 : Approval of the Secretariat’s Recommendation on Funding from the 2021 COVID-19 Response Mechanism 1 Document Classification: Internal. Document Circulation: Board Members, Alternate Board Members, Constituency Focal Points and Committee Members. This document may be shared by the Focal Points within their respective Board constituency. The document must not however be subject to any further circulation or otherwise be made public. 1 The Secretariat recommends the approval of funding from the 2021 COVID-19 Response Mechanism for Multicountry ECSA-HC, up to an amount of US$ 1,819,230 . Decision | Decision Point: GF/B46/EDP18: Approval of the Secretariat’s Recommendation | | --- | | on Funding from the COVID-19 Response Mechanism
The Board:
a. Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$45 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
b. Approves the funding recommended for each country, as listed in Table 1 of GF/B4 6/ER14; and
c. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP1 8.
This decision does not raise new, material budgetary implications for operating expenses. | Executive Summary Context and Input Received Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (C19RM) The Secretariat recommends the approval of funding from C19RM for Multicountry East, Central and Southern Africa Health Community ( ECSA-HC) , up to an amount of US$1,819,230 . The country awards in Table 1 are recommended by the Secretariat following internal review processes , which included input from a C19RM Technical Advisory Group of relevant ACT-Accelerator partners (CTAG) and GAC partners. For each country funding request, the Secretariat reviewed (i) the strategic focus of the investment; (ii) alignment with WHO technical guidance, the C19RM Technical Information Note, the National Strategic Preparedness and Response Plan for COVID-19 and guidance from partners on alignment with the HIV, TB and malaria mitigation plans in the country; (iii) linkages with underlying grants and service disruption for human immunodeficiency virus (HIV) , tuberculosis (TB) and malaria programs; (iv) alignment with principles of stakeholder and community engagement, gender equity and human rights; (v) availability of appropriate procurement channels (global availability and sourcing implication of the health products requested to be procured), especially related to supply-side aspects, including the availability of scarce products; (vi) the technical soundness of the request and expected outcomes; (vii) the feasibility and assumptions of proposed activities and the associated budget, including performance and absorption of C19RM 2020 awards;(viii) complementarity/potential duplication with other available sources of funding; (ix) residual risks, including associated fiduciary risks related to implementation arrangements and/or interventions, and mitigating and assurance measures to ensure that funds are used for intended purposes; and (x) value for money. A list of documents per applicant for Multi-country requests to substantiate the Board decision is provided below. • C19RM Funding Request; • C19RM budget (as revised for final recommendation for Board approval, if applicable); • List of health products (as revised, if applicable); • National Stra

FAQs

What decision point does the paper seek approval for?

Approval is requested for the decision point GF/B46/EDP18: Approval of the Secretariat’s Recommendation on Funding from the 2021 COVID-19 Response Mechanism.

What funding amount is recommended for Multicountry ECSA-HC under the 2021 C19RM?

The Secretariat recommends approval of funding for Multicountry ECSA-HC up to US$1,819,230.

What criteria did the Secretariat use to review each country funding request?

The Secretariat reviewed strategic focus, alignment with WHO and C19RM guidance and national plans, linkages to HIV/TB/malaria program disruptions, stakeholder and gender equity principles, procurement channel feasibility, technical soundness and expected outcomes, budget feasibility and absorption assumptions, complementarity with other funding, residual fiduciary risks and mitigation measures, and value for money.

Sep 12, 2026

Upload by Đào